113 related articles for article (PubMed ID: 11170624)
1. Estimation of binding affinities for HEPT and nevirapine analogues with HIV-1 reverse transcriptase via Monte Carlo simulations.
Rizzo RC; Tirado-Rives J; Jorgensen WL
J Med Chem; 2001 Jan; 44(2):145-54. PubMed ID: 11170624
[TBL] [Abstract][Full Text] [Related]
2. Prediction of activity for nonnucleoside inhibitors with HIV-1 reverse transcriptase based on Monte Carlo simulations.
Rizzo RC; Udier-Blagović M; Wang DP; Watkins EK; Kroeger Smith MB; Smith RH; Tirado-Rives J; Jorgensen WL
J Med Chem; 2002 Jul; 45(14):2970-87. PubMed ID: 12086483
[TBL] [Abstract][Full Text] [Related]
3. Prediction of binding affinities for TIBO inhibitors of HIV-1 reverse transcriptase using Monte Carlo simulations in a linear response method.
Smith RH; Jorgensen WL; Tirado-Rives J; Lamb ML; Janssen PA; Michejda CJ; Kroeger Smith MB
J Med Chem; 1998 Dec; 41(26):5272-86. PubMed ID: 9857095
[TBL] [Abstract][Full Text] [Related]
4. Molecular modeling calculations of HIV-1 reverse transcriptase nonnucleoside inhibitors: correlation of binding energy with biological activity for novel 2-aryl-substituted benzimidazole analogues.
Kroeger Smith MB; Hose BM; Hawkins A; Lipchock J; Farnsworth DW; Rizzo RC; Tirado-Rives J; Arnold E; Zhang W; Hughes SH; Jorgensen WL; Michejda CJ; Smith RH
J Med Chem; 2003 May; 46(10):1940-7. PubMed ID: 12723956
[TBL] [Abstract][Full Text] [Related]
5. Docking-MM-GB/SA and ADME screening of HIV-1 NNRTI inhibitor: nevirapine and its analogues.
Sengupta D; Verma D; Naik PK
In Silico Biol; 2008; 8(3-4):275-89. PubMed ID: 19032162
[TBL] [Abstract][Full Text] [Related]
6. Bridge water mediates nevirapine binding to wild type and Y181C HIV-1 reverse transcriptase--evidence from molecular dynamics simulations and MM-PBSA calculations.
Treesuwan W; Hannongbua S
J Mol Graph Model; 2009; 27(8):921-9. PubMed ID: 19414275
[TBL] [Abstract][Full Text] [Related]
7. Modelling the binding of HIV-reverse transcriptase and nevirapine: an assessment of quantum mechanical and force field approaches and predictions of the effect of mutations on binding.
Raju RK; Burton NA; Hillier IH
Phys Chem Chem Phys; 2010 Jul; 12(26):7117-25. PubMed ID: 20480085
[TBL] [Abstract][Full Text] [Related]
8. Effect of a bound non-nucleoside RT inhibitor on the dynamics of wild-type and mutant HIV-1 reverse transcriptase.
Zhou Z; Madrid M; Evanseck JD; Madura JD
J Am Chem Soc; 2005 Dec; 127(49):17253-60. PubMed ID: 16332074
[TBL] [Abstract][Full Text] [Related]
9. Docking, molecular dynamics and quantitative structure-activity relationship studies for HEPTs and DABOs as HIV-1 reverse transcriptase inhibitors.
Mao Y; Li Y; Hao M; Zhang S; Ai C
J Mol Model; 2012 May; 18(5):2185-98. PubMed ID: 21947448
[TBL] [Abstract][Full Text] [Related]
10. A dipyrido [2,3-b:3',2'-f]azepine analog of the HIV-1 reverse transcriptase inhibitor nevirapine.
Dyatkin AB; Brickwood JR; Proudfoot JR
Bioorg Med Chem Lett; 1998 Aug; 8(16):2169-72. PubMed ID: 9873507
[TBL] [Abstract][Full Text] [Related]
11. Design of nevirapine derivatives insensitive to the K103N and Y181C HIV-1 reverse transcriptase mutants.
Saparpakorn P; Hannongbua S; Rognan D
SAR QSAR Environ Res; 2006 Apr; 17(2):183-94. PubMed ID: 16644557
[TBL] [Abstract][Full Text] [Related]
12. Structural insights into mechanisms of non-nucleoside drug resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138.
Ren J; Nichols CE; Stamp A; Chamberlain PP; Ferris R; Weaver KL; Short SA; Stammers DK
FEBS J; 2006 Aug; 273(16):3850-60. PubMed ID: 16911530
[TBL] [Abstract][Full Text] [Related]
13. The molecular basis of resilience to the effect of the Lys103Asn mutation in non-nucleoside HIV-1 reverse transcriptase inhibitors studied by targeted molecular dynamics simulations.
Rodríguez-Barrios F; Balzarini J; Gago F
J Am Chem Soc; 2005 May; 127(20):7570-8. PubMed ID: 15898808
[TBL] [Abstract][Full Text] [Related]
14. Validation of a model for the complex of HIV-1 reverse transcriptase with nonnucleoside inhibitor TMC125.
Udier-Blagović M; Tirado-Rives J; Jorgensen WL
J Am Chem Soc; 2003 May; 125(20):6016-7. PubMed ID: 12785806
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 reverse transcriptase variants: molecular modeling of Y181C, V106A, L100I, and K103N mutations with nonnucleoside inhibitors using Monte Carlo simulations in combination with a linear response method.
Smith MB; Ruby S; Horouzhenko S; Buckingham B; Richardson J; Puleri I; Potts E; Jorgensen WL; Arnold E; Zhang W; Hughes SH; Michejda CJ; Smith RH
Drug Des Discov; 2003; 18(4):151-63. PubMed ID: 15553926
[TBL] [Abstract][Full Text] [Related]
16. Estimation of binding affinities for selective thrombin inhibitors via Monte Carlo simulations.
Pierce AC; Jorgensen WL
J Med Chem; 2001 Mar; 44(7):1043-50. PubMed ID: 11297451
[TBL] [Abstract][Full Text] [Related]
17. Quantum computational analysis for drug resistance of HIV-1 reverse transcriptase to nevirapine through point mutations.
He X; Mei Y; Xiang Y; Zhang DW; Zhang JZ
Proteins; 2005 Nov; 61(2):423-32. PubMed ID: 16114038
[TBL] [Abstract][Full Text] [Related]
18. Docking of non-nucleoside inhibitors: neotripterifordin and its derivatives to HIV-1 reverse transcriptase.
Zhou Z; Madrid M; Madura JD
Proteins; 2002 Dec; 49(4):529-42. PubMed ID: 12402361
[TBL] [Abstract][Full Text] [Related]
19. Three-dimensional quantitative structure-activity relationships study on HIV-1 reverse transcriptase inhibitors in the class of dipyridodiazepinone derivatives, using comparative molecular field analysis.
Pungpo P; Hannongbua S
J Mol Graph Model; 2000 Dec; 18(6):581-90, 601. PubMed ID: 11155314
[TBL] [Abstract][Full Text] [Related]
20. Field-based similarity forcing in energy minimization and molecular matching.
Blinn JR; Rohrer DC; Maggiora GM
Pac Symp Biocomput; 1999; ():415-25. PubMed ID: 10380215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
